v3.26.1
Description of Business and Significant Accounting Policies - Additional Information (Detail)
€ in Millions
1 Months Ended 6 Months Ended
Dec. 31, 2023
Jan. 31, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2026
USD ($)
Segment
Jun. 30, 2025
USD ($)
Jun. 30, 2026
EUR (€)
Dec. 31, 2025
USD ($)
Jul. 01, 2013
USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                
Percentage of future royalties       1.00%        
Number of operating segment | Segment       1        
Number of reportable segment | Segment       1        
Revenue recognized related to milestone       $ 0        
Purchase of available-for-sale securities       $ 10,301,000 $ 88,127,000      
Loss on purchase commitments | €           € 55.2    
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]       srt:ChiefExecutiveOfficerMember, srt:ChiefFinancialOfficerMember        
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description       The key metric utilized by the CODM to assess resource allocation and performance is the Company’s segment net income, which is the same as the consolidated net income reported in the condensed consolidated statements of operations. The CODM also analyzes the Company's consolidated net income to evaluate its return on segment assets and to establish budgets and forecasts.        
Sagard                
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                
Percentage of royalty on future net sales 1.00%              
Insulin                
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                
Loss on purchase commitments       $ 64,100,000     $ 66,000,000  
Tyvaso DPI                
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                
Percentage of royalty on net sales       10.00%        
Percentage of royalty on net revenue       10.00%        
Percentage of future royalties       9.00%        
Maximum | AFREZZA product sales                
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                
Sales return right following product expiration in months       12 months        
Minimum | AFREZZA product sales                
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                
Sales return right following product expiration in months       6 months        
Convertible Promissory Note | Thirona Bio, Inc.                
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                
Purchase of available-for-sale securities   $ 5,000,000 $ 3,000,000          
Milestone Rights Liability | Deerfield                
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                
Contingent liability for milestone payments       $ 45,000,000        
Milestone Rights Liability | Maximum | Deerfield                
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                
Contingent liability for milestone payments               $ 90,000,000